Roche warns Germany faces last chance to regain pharma investment confidence

Roche has said that recent German healthcare reforms threaten the country's attractiveness for pharmaceutical investment. The company paused its own German investment plans after the reforms were announced, joining Boehringer Ingelheim and Eli Lilly, which withdrew roughly €2 billion in planned spending.

Roche’s German head described the new legislation as a heavy burden on research‑based pharma firms and said it sends a negative signal to investors. The firm views the proposed clause in the upcoming reforms as a final opportunity for Germany to restore trust and keep future projects viable.

German lawmakers are considering the clause, which would take effect on Jan. 1, as part of broader health‑budget cuts. The outcome will be closely watched by the industry, as it could determine whether additional multinational drug makers keep or pull back their German investments.